UvA-DARE is a service provided by the library of the University of Amsterdam (https://dare.uva.nl)
UvA-DARE (Digital Academic Repository)
Infection with HIV-1 induces a decrease in mtDNA
Casula, M.; Bosboom-Dobbelaer, I.; Smolders, K.; Otto, S.A.; Bakker, M.; de Baar, M.P.;
Reiss, P.; de Ronde, A.
DOI
10.1086/429412
Publication date
2005
Published in
The Journal of Infectious Diseases
Link to publication
Citation for published version (APA):
Casula, M., Bosboom-Dobbelaer, I., Smolders, K., Otto, S. A., Bakker, M., de Baar, M. P.,
Reiss, P., & de Ronde, A. (2005). Infection with HIV-1 induces a decrease in mtDNA. The
Journal of Infectious Diseases, 191(9), 1468-1471. https://doi.org/10.1086/429412
General rights
It is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), other than for strictly personal, individual use, unless the work is under an open content license (like Creative Commons).
Disclaimer/Complaints regulations
If you believe that digital publication of certain material infringes any of your rights or (privacy) interests, please let the Library know, stating your reasons. In case of a legitimate complaint, the Library will make the material inaccessible and/or remove it from the website. Please Ask the Library: https://uba.uva.nl/en/contact, or a letter to: Library of the University of Amsterdam, Secretariat, Singel 425, 1012 WP Amsterdam, The Netherlands. You will be contacted as soon as possible.
B R I E F R E P O R T
Infection with HIV-1 Induces
a Decrease in mtDNA
Miriam Casula,1Irene Bosboom-Dobbelaer,2Karlijn Smolders,2
Sigrid Otto,3Margreet Bakker,4Michel P. de Baar,2Peter Reiss,5
and Anthony de Ronde4
1International Antiviral Therapy Evaluation Center,2Primagen,3Department
of Clinical Viro-Immunology, Sanquin Research at Central Laboratory Blood Transfusion Service, and Departments of4Human Retrovirology and5Internal
Medicine, Division of Infectious Diseases, Tropical Medicine and AIDS, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Cross-sectional studies have suggested that infection with human immunodeficiency virus (HIV) type 1 could reduce the mitochondrial DNA (mtDNA) content of blood cells. We investigated mtDNA content in peripheral blood mononu-clear cells (PBMCs) obtained from 36 antiretroviral therapy– naive documented HIV-1 seroconverters, before and after seroconversion. mtDNA content statistically significantly de-creased 1 year after seroconversion and showed a nonsig-nificant decrease during the subsequent 4 years. These find-ings confirm that infection with HIV-1 may, itself, reduce mtDNA content, at least within PBMCs. This could have implications for the subsequent development of mitochon-drial toxicities associated with the use of nucleoside analogue reverse-transcriptase inhibitors.
Immunodeficiency is the hallmark of HIV-1 infection. The avail-ability of highly active antiretroviral therapy (HAART) for HIV-1 infection has led to a dramatic decrease in mortality and disease progression, causing HIV-1 infection to assume the character-istics of a chronic disease. Nucleoside analogue reverse-transcrip-tase inhibitors (NRTIs) are major components of HAART and are known to inhibit in vitro DNA polymerase-g, the enzyme responsible for mtDNA replication, to various extents [1]. In pa-tients, NRTIs, by way of their effects on mitochondria, have been suggested to contribute to a range of treatment-associated adverse effects, which include peripheral neuropathy, myopathy (includ-ing cardiomyopathy), hepatic steatosis, lactic acidosis, and
pe-Received 11 October 2004; accepted 10 December 2004; electronically published 25 March 2005.
Reprints or correspondence: Miriam Casula, Meibergdreef 9, PO Box 22700, 1100 DE Am-sterdam, The Netherlands (m.casula@amc.uva.nl, m.casula@iatec.com).
The Journal of Infectious Diseases 2005; 191:1468–71
2005 by the Infectious Diseases Society of America. All rights reserved. 0022-1899/2005/19109-0013$15.00
ripheral lipoatrophy [1]. HIV-1 infection itself may cause various complications, including peripheral neuropathy, cardiomyopa-thy, wasting, and nephropathy [2]. Interestingly, some of these complications resemble the aforementioned adverse effects of NRTIs. One could therefore speculate that HIV-1 infection itself has adverse effects on mitochondria. In fact, the results of recent cross-sectional studies, which included HIV-1 infected patients receiving HAART as well as those who were therapy naive and uninfected control subjects, have indeed suggested that HIV-1 infection may be responsible for a decrease in mtDNA in pe-ripheral blood mononuclear cells (PBMCs) [3–5]. To address more directly the question of whether HIV-1 infection may result in mtDNA depletion, we performed a longitudinal study in which we assessed the mtDNA content in PBMCs obtained from a group of individuals with documented HIV-1 seroconversion.
Patients and methods. The Amsterdam Cohort Study (ACS) was set up between October 1984 and March 1986—961 asymp-tomatic men living in and around Amsterdam who had multiple homosexual contacts were enrolled in a prospective study of HIV infection and AIDS. Clinical and epidemiological data were col-lected, and blood samples were drawn every ∼3 months for serological and immunological assessment, as well as for storage of both serum and PBMCs for future studies. Written, informed consent was obtained from all participants. This resulted in a cohort consisting of men who were found to already be HIV-1 seropositive at entry, as well as men who were seronegative and remained so or who seroconverted during follow-up.
The samples in our study consisted of serial collections of cryopreserved PBMCs from 36 men with documented HIV-1 seroconversion who had been enrolled in the ACS. Presero-conversion samples had been obtained at a median of 3 years (interquartile range [IQR], 1–6 years) before seroconversion. Postseroconversion samples were selected that had been ob-tained at∼1 and ∼5 years after seroconversion. Participant se-lection from the overall group of documented HIV-1 serocon-verters in the ACS was determined by the availability of samples at the repository laboratory and whether antiretroviral therapy (ART) had been administered within the period of observation after seroconversion. The moment of seroconversion was con-sidered to be time point 0.
Patient PBMCs were obtained from the repository labora-tory, where they had been freshly isolated from heparinized blood by means of the Ficoll-Hypaque method and then cryo-preserved in liquid nitrogen by use of an automated freezing program. Before lysis with L6, a lysis buffer that contains chao-tropic guanidinium thiocyanate [6], all PBMCs were thawed
Figure 1. Box-whisker plots of logarithmically transformed mtDNA values (copies/cell), relative to time before seroconversion (presero) and 1 and 5 years after seroconversion (1 yr post and 5 yrs post, respectively). The plot illustrates the median (middle line), interquartile range (top and
bottom of each box), and the reference interval containing the central
95% of the distribution.
Figure 2. Box-whisker plots of CD4+and CD8+cell count, relative to
time before seroconversion (presero) and 1 and 5 years after serocon-version (1 yr post and 5 yrs post, respectively).
and washed, thereby limiting contamination with platelets to a level that did not alter the result of mtDNA quantification [7, 8]. Total DNA was extracted from an equivalent amount of3⫻ 105patient PBMCs by use of the silica-based method of Boom et al. [6]. An amount of total nucleic acid equivalent to cells was used as input in the amplification reaction,
3
3⫻ 10
and each sample was tested in duplicate. As a calibrator, known amounts of plasmid mtDNA and nuclear DNA (nDNA) were mixed and included in each assay.
mtDNA and nDNA of each isolate were simultaneously am-plified by means of real-time duplex nucleic acid sequence– based amplification (Retina Mitox). Results for each isolate were calculated as the mean value of the mtDNA:nDNA ratios of duplicate measurements. In addition, patient data such as age and laboratory measurements—including HIV-1 load and CD4+ and CD8+ cell counts in peripheral blood—were also
retrieved from the ACS database. Although the objective of the study was to determine the relationship between the relative time since seroconversion and changes in mtDNA content per cell, the effect of other parameters (i.e., age) was also taken in-to consideration.
Changes in the number of mtDNA copies per cell among the 3 available time points were assessed by use of the paired Student’s t test. mtDNA data were logarithmically transformed, to obtain a normal distribution. The change in mtDNA content per cell was also expressed as a percentage relative to the pre-seroconversion value. Spearman’s correlation analysis was used to determine any association between mtDNA content and both immunological parameters and HIV-1 load after seroconver-sion. At 1 and 5 years after seroconversion, the association
be-tween the change in mtDNA content and HIV-1 load was also examined. Group size in the analyses was determined by the availability of samples at the 3 time points and of CD4+, CD8+,
and HIV-1 load data from the ACS database. Furthermore, a correction by exclusion was made for the use of ART. Analyses were conducted by use of SPSS (version 11.0 for Windows; SPSS). The level of significance was set atP!.05throughout the analysis.
Results Although all 36 patients were therapy naive at 1 year after seroconversion, only 18 remained therapy naive and had samples available at 5 years after seroconversion. The re-maining 18 patients were excluded from the analysis at 5 years after seroconversion, because of unavailability of samples (n p10) or the commencement of ART (n p 8).
mtDNA content decreased significantly, from a median of 264 copies/cell (IQR, 202–404 copies/cell) before seroconver-sion to a median of 234 copies/cell (IQR, 178–306 copies/cell) 1 year after seroconversion (P p .004) (figure 1). In terms of the percentage relative to preseroconversion values, the mtDNA content 1 year after seroconversion decreased significantly, by 11% (95% confidence interval, 2%–21%).
Although mtDNA content showed an additional decrease be-tween 1 (median, 240 copies/cell [IQR, 196–279 copies/cell]) and 5 (median, 213 copies/cell [IQR, 177–293 copies/cell]) years after seroconversion, this did not reach statistical signif-icance (P p .894) (figure 1). At the time points assessed, char-acteristic trends in CD4+and CD8+cell counts were observed.
There was a significant decrease (P!.001) in CD4+cell count
(figure 2) from preseroconversion values (median, 761 cells/ mm3 [IQR, 578–960 cells/mm3]) through 5 years after
sero-conversion (median, 480 cells/mm3[IQR, 345–600 cells/mm3]),
whereas the CD8+cell count increased significantly between 1
(me-dian, 875 cells/mm3
[IQR, 782–1303 cells/mm3
]) years after se-roconversion (P p .001). Analysis of the mtDNA content within fractionated CD4+and CD8+cells from a healthy donor showed
identical mtDNA content (270 copies/cell) for each of these 2 cell types (data not shown), which suggests that changes in the CD4+
:CD8+
ratio cannot explain the altered mtDNA content of PBMCs that we found.
Cross-sectional and longitudinal analysis of the association between mtDNA and CD4+cell count, CD8+cell count, or
HIV-1 load did not yield any statistically significant results (data not shown). Furthermore, the mtDNA content in PBMCs at the preseroconversion time point was not influenced by partici-pants’ age (r p 0.004 P p .7142 ; ), which indicates that old-er age does not explain the decrease in mtDNA aftold-er infection with HIV-1. Although the individuals in the ACS might have been exposed to other factors, such as hepatitis coinfection, because of a lack of data, we could not determine the effects of these additional factors on mtDNA.
Discussion. Our longitudinal study confirms the finding from earlier cross-sectional studies that HIV-1 infection, in the absence of any ART, is associated with a decrease in the mtDNA content of PBMCs. The mechanism underlying this mtDNA decrease remains to be established. However, considering that mtDNA, under normal circumstances, may already be exposed to reactive oxygen species (ROS) produced within mitochon-dria [9], increased generation of ROS in response to viral in-fection might further affect mtDNA integrity by inducing mu-tations and deletions, which possibly leads to a measurable decrease [10, 11]. Furthermore, certain HIV-1–encoded pro-teins, such as Vpr, have been shown to adversely affect mito-chondrial integrity [12], which may occur both in HIV-1–in-fected cells and in surrounding uninHIV-1–in-fected bystander cells [13]. This possibly renders the normal ROS scavenging mechanism ineffective, resulting in accelerated damage to mtDNA in such cells and in apoptosis and thereby contributing to certain HIV-1–associated disease manifestations. One may expect that, un-der such circumstances, tissues with a high energy demand— such as nervous tissue, cardiac muscle, and renal tissue—would be the ones most affected. Furthermore, the analysis performed on samples from 18 ART-naive patients showed that mtDNA in PBMCs continued to decrease throughout the 5 years after seroconversion, although the decrease did not reach statistical significance. The statistical power of our analysis was limited, however, by the availability of samples.
In agreement with our data, both functional mitochondrial damage and a decrease in mtDNA in PBMCs in HIV-infected subjects, compared with healthy control subjects, has been re-ported by a number of other investigators [3–5, 14], whereas others have reported no significant difference in mtDNA con-tent [15]. The discrepancy between the results of these cross-sectional studies has yet to be explained.
In conclusion, our results are consistent with the concept that HIV-1 infection itself may be responsible for a decrease in mtDNA within PBMCs. Although subsequent treatment with ART, including NRTIs, may further aggravate the decrease in mtDNA by inhibiting DNA polymerase-g and, thereby, possibly rendering patients more prone to developing certain NRTI tox-icities, the suppression of HIV-1 infection may be expected to exert a restorative effect on mtDNA. The net effect of these 2 counteracting factors may ultimately represent the balance be-tween the intrinsic mitochondrial toxicity of the specific NRTIs in the regimen and the overall antiviral potency of the ART regimen.
Acknowledgments
We thank all the participants of the Amsterdam Cohort Study, for their continued contribution; Gerrit Jan Weverling, for help with the design of the study; and Ferdinand Wit, for assistance with the analysis of the results and for critically reviewing the manuscript.
References
1. Martin JL, Brown CE, Matthews-Davis N, Reardon JE. Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob Agents Chemother 1994; 38:2743–9.
2. Moroni M, Antinori S. HIV and direct damage of organs: disease spec-trum before and during the highly active antiretroviral therapy era. AIDS 2003; 17(Suppl 1):S51–64.
3. Cote HC, Brumme ZL, Craib KJ, et al. Changes in mitochondrial DNA as a marker of nucleoside toxicity in HIV-infected patients. N Engl J Med 2002; 346:811–20.
4. Miro´ O, Lo´pez S, Martı´nez E, et al. Mitochondrial effects of HIV infection on the peripheral blood mononuclear cells of HIV-infected patients who were never treated with antiretrovirals. Clin Infect Dis 2004; 39:710–6. 5. Miura T, Goto M, Hosoya N, et al. Depletion of mitochondrial DNA
in HIV-1–infected patients and its amelioration by antiretroviral ther-apy. J Med Virol 2003; 70:497–505.
6. Boom R, Sol CJ, Salimans MM, Jansen CL, Wertheim–van Dillen PM, van der Noordaa J. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990; 28:495–503.
7. de Baar MP, Dobbelaer I, Timmermans EC, et al. Declined mitochon-drial DNA levels in peripheral blood mononuclear cells due to HIV infection can further decline or rise depending on the mitochondrial toxicity of the used antiviral drug combination [abstract 49]. Antivir Ther 2003; 8:37–8.
8. Banas B, Kost BP, Goebel FD. Platelets, a typical source of error in real-time PCR quantification of mitochondrial DNA content in human peripheral blood cells. Eur J Med Res 2004; 9:371–7.
9. Richter C, Park JW, Ames BN. Normal oxidative damage to mito-chondrial and nuclear DNA is extensive. Proc Natl Acad Sci USA 1988; 85:6465–7.
10. Akaike T, Suga M, Maeda H. Free radicals in viral pathogenesis: mo-lecular mechanisms involving superoxide and NO. Proc Soc Exp Biol Med 1998; 217:64–73.
11. Ide T, Tsutsui H, Hayashidani S, et al. Mitochondrial DNA damage and dysfunction associated with oxidative stress in failing hearts after myocardial infarction. Circ Res 2001; 88:529–35.
12. Jacotot E, Ferri KF, El Hamel C, et al. Control of mitochondrial membrane permeabilization by adenine nucleotide translocator inter-acting with HIV-1 viral protein rR and Bcl-2. J Exp Med 2001; 193: 509–19.
13. Arunagiri C, Macreadie I, Hewish D, Azad A. A C-terminal domain of HIV-1 accessory protein Vpr is involved in penetration, mitochon-drial dysfunction and apoptosis of human CD4+lymphocytes.
Apo-ptosis 1997; 2:69–76.
14. Chiappini F, Teicher E, Saffroy R, et al. Prospective evaluation of blood concentration of mitochondrial DNA as a marker of toxicity in 157
consecutively recruited untreated or HAART-treated HIV-positive pa-tients. Lab Invest 2004; 84:908–14.
15. Petit C, Mathez D, Barthelemy C, et al. Quantitation of blood lym-phocyte mitochondrial DNA for the monitoring of antiretroviral drug-induced mitochondrial DNA depletion. J Acquir Immune Defic Syndr 2003; 33:461–9.
